About: Persisting SARS‐CoV‐2 viremia after rituximab therapy: Two cases with fatal outcome and a review of literature

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Persisting SARS‐CoV‐2 viremia after rituximab therapy: Two cases with fatal outcome and a review of literature Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Persisting SARS‐CoV‐2 viremia after rituximab therapy: Two cases with fatal outcome and a review of literature
Creator	Kühn, Joachim Hafezi, Wali Keller, Martin Lutz, Mathias Sackarnd, Jan Schmidt, Hartmut Tepasse, Phil-Robin Vollenberg, Richard Wiewrodt, Rainer Wilms, Christian
Source	Medline; PMC
abstract	BACKGROUND: COVID‐19 is an emerging infectious disease caused by SARS‐CoV‐2. The role of immunosuppression in disease course is not clear. Here we describe the lethal disease course in two SARS‐CoV‐2 infected patients after rituximab therapy. METHODS: Clinical data and laboratory findings of two SARS‐CoV‐2 infected rituximab treated patients were collected. SARS‐CoV‐2 RNA was detected in blood. RESULTS: Both patients developed severe respiratory failure. SARS‐CoV‐2 viremia persisted in both patients until they died on day 22 and 26 after admission. CONCLUSION: Rituximab therapy leads to severe combined immunodeficiency and these two cases indicate a high risk for fatal outcome after SARS‐CoV‐2 infection.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1111/bjh.16896
bibo:pmid	32557623
has license	no-cc
sha1sum (hex)	52653346b36a5f6f0c74850d6d99795aea7b09f3
schema:url	https://doi.org/10.1111/bjh.16896
resource representing a document's title	Persisting SARS‐CoV‐2 viremia after rituximab therapy: Two cases with fatal outcome and a review of literature
has PubMed Central identifier	PMC7300950
has PubMed identifier	32557623
schema:publication	Br J Haematol
resource representing a document's body	covid:52653346b36a5f6f0c74850d6d99795aea7b09f3#body_text
is schema:about of	named entity 'caused' named entity 'therapy' named entity 'cases' covid:arg/52653346b36a5f6f0c74850d6d99795aea7b09f3 named entity 'SARS-CoV-2' named entity 'infected' named entity 'rituximab' named entity 'SARS-CoV-2' named entity 'immunocompromised patients' named entity 'qRT-PCR' named entity 'viruses' named entity 'B-cell' named entity 'zoonotic' named entity 'Wuhan' named entity 'immunoglobulin' named entity 'proinflammatory' named entity 'higher risk' named entity 'SARS-CoV-2' named entity 'rituximab' named entity 'interact' named entity 'COVID-19' named entity 'RNA extraction' named entity 'chest x-rays' named entity 'hematological malignancies' named entity 'Carboplatin' named entity 'immunosuppressive drugs' named entity 'normal weight' named entity 'plasma' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'infection' named entity 'infection' named entity 'immunocompromised' named entity 'peripheral blood' named entity 'coronaviruses' named entity 'SARS-CoV-2' named entity 'fluorescence' named entity 'COVID' named entity 'Rituximab' named entity 'China' named entity 'relapse' named entity 'Influenza infection' named entity 'SARS-CoV-2' named entity 'RdRP' named entity 'respiratory failure' named entity 'risk factor' named entity 'positive controls' named entity 'anti-CD20' named entity 'Virus' named entity 'chronic renal insufficiency' named entity 'real-time PCR' named entity 'patient history' named entity 'SARS-CoV-2' named entity 'infection' named entity 'Rituximab' named entity 'SARS-CoV-2' named entity 'respiratory failure' named entity 'infection' named entity 'Rituximab' named entity 'Viremia' named entity 'immunosuppressive treatment' named entity 'plasma' named entity 'Dexamethason' named entity 'haematological malignancies' named entity 'chronic disease' named entity 'cell cycle' named entity 'cytokine storm' named entity 'virus' named entity 'Wuhan' named entity 'B-cell' named entity 'ThermoFisher' named entity 'RT-PCR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software